Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Core Viewpoint - Structure Therapeutics Inc. has announced a proposed underwritten public offering to issue and sell $500 million of American depositary shares (ADSs) to support its development of novel oral small molecule therapeutics for metabolic diseases, particularly obesity [1] Group 1: Offering Details - The company plans to grant underwriters a 30-day option to purchase up to an additional $75 million of ADSs or pre-funded warrants [2] - The offering is made under an automatic shelf registration statement on Form S-3, which was filed with the SEC on August 6, 2025 [4] Group 2: Management and Coordination - Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering [3] Group 3: Company Overview - Structure Therapeutics is focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs, utilizing a next-generation structure-based drug discovery platform [6]